Citadel Advisors’s HUTCHMED HCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-9,600
Closed -$144K 13534
2025
Q1
$144K Buy
9,600
+400
+4% +$5.92K ﹤0.01% 10935
2024
Q4
$133K Buy
9,200
+8,100
+736% +$145K ﹤0.01% 11071
2024
Q3
$21.5K Sell
1,100
-1,300
-54% -$23.5K ﹤0.01% 12725
2024
Q2
$41.1K Sell
2,400
-1,300
-35% -$24K ﹤0.01% 11965
2024
Q1
$62.2K Buy
3,700
+1,600
+76% +$24.3K ﹤0.01% 11961
2023
Q4
$38K Buy
2,100
+600
+40% +$10.9K ﹤0.01% 12056
2023
Q3
$25.4K Sell
1,500
-500
-25% -$7.16K ﹤0.01% 12419
2023
Q2
$24K Sell
2,000
-2,600
-57% -$35.5K ﹤0.01% 12572
2023
Q1
$59.9K Buy
4,600
+4,400
+2,200% +$72.1K ﹤0.01% 11934
2022
Q4
$2.96K Buy
+200
New +$2.19K ﹤0.01% 14267
2021
Q3
Sell
-9,900
Closed -$389K 14134
2021
Q2
$389K Buy
+9,900
New +$286K ﹤0.01% 10636

Other funds holding HCM

Citadel Advisors's HCM Position: Q1 2026 in Review

Citadel Advisors increased its HUTCHMED (HCM) stake by 18% in Q1 2026, buying an estimated $69.4K and bringing the position to 30,514 shares worth $456K. The position accounts for ﹤0.01% of the portfolio, ranked #9520.

Citadel Advisors first reported a position in HCM in Q1 2018 and has held it in 26 quarters since. The position peaked at $3.21M in Q4 2022. 54 funds tracked by Wall St. Rank hold HCM as of Q1 2026.

  • Citadel Advisors held 30,514 shares of HUTCHMED worth $456K as of Q1 2026.
  • Citadel Advisors bought 4,747 HUTCHMED shares in Q1 2026, an estimated $69.4K.
  • HUTCHMED made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9520 holding.
  • Citadel Advisors first reported a position in HUTCHMED in Q1 2018 and has held it in 26 quarters since.
  • Citadel Advisors's HUTCHMED position peaked at $3.21M in Q4 2022.
  • 54 funds tracked by Wall St. Rank held HUTCHMED as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.